TG Therapeutics (TGTX) Misses Q3 EPS by 19c

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $30 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Wendy's U.S. president to resign, company to create COO role
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low